Apricus announced Aug 18 that it got the FDA’s go-ahead to sell an anti-fungal drug called Tolnaftate-D. The anti-fungal cream incorporates Apricus’ NexACT technology which is expected to be used in several other products.

Apricus announced Aug 18 that it got the FDA’s go-ahead to sell an anti-fungal drug called Tolnaftate-D. The anti-fungal cream incorporates Apricus’ NexACT technology which is expected to be used in several other products.

APRICUS BIOSCIENCES INC.

President and CEO: Bassam Damaj.

Revenue: $4.97 million in 2010; $2.97 million in 2009.

Net loss: $29.51 million in 2010; $32.04 million in 2009.

No. of local employees: 20.

Headquarters: San Diego’s Sorrento Valley area.

Year founded: 1987.

Stock symbol and exchange: APRI on Nasdaq.

Company description: A pharmaceutical research and development company with multiple products centered on its patented drug delivery system, NexACT. Therapeutic areas include oncology, sexual dysfunction, autoimmune diseases, and inflammation.

August has been a huge month for San Diego-based Apricus Biosciences Inc...

Take 1 minute to subscribe and you'll get this story immediately, plus:

Already a subscriber? Sign in

  • 52 weekly issues
  • Subscriber-only digital content every business day, plus full access to SDBJ.com archives
  • Book of Lists — the most comprehensive business resource in San Diego
  • NEW: San Diego 500 — influential business leaders you need to know
Yours for only $129